Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression
- 52 Downloads
The American healthcare market is currently estimated at more than $US900 billion with double digit rising costs per year. Psychotropic agent costs have more than kept pace with market increases. Medication acquisition costs are an obvious focus for limiting costs in various care systems.
Restrictive formularies are a common method of attempting to limit costs. To support our opinion that a single agent is ill advised, we explored the available evidence on the intended and unintended consequences of having a single or exclusive selective serotonin reuptake inhibitor (SSRI) on a formulary. Central to this position is an assumption of the interchangeability of SSRIs; we examined the evidence for and against this through a model to determine the probability of interchangeability. We conclude that the practice of having a single SSRI on the formulary for a healthcare plan seems ill founded. Patients who switch antidepressants remain in treatment 50% longer and cost approximately 50% more to treat in a more costly treatment setting.
Giving the primary care physician several antidepressant choices can provide more options to continue treatment of his or her patient in the less expensive primary care setting. In terms of cost containment, formulary restrictions are far more likely to have the opposite effect.
KeywordsFluoxetine Paroxetine Selective Serotonin Reuptake Inhibitor Antidepressant Medication Health Maintenance Organisation
- 2.Narrow WE. One-year prevalence of depressive disorders among adults 18 and over in the US. NIMH ECA prospective data. Population estimates based on U.S. Census estimated residential population age 18 and over on July 1, 1998 (reprinted from http://www.nimh.nih.gov/publicat/numbers.cfm#1)
- 3.Kohl M. Maelstrom in Michigan over medication. Mental Health Economics Supplement to Psychiatric Times 2000 Mar: 6–7Google Scholar
- 10.Alchin TM, Tranby HW. Who bears the cost of antidepressant in Australia? Med J Aust 1994 Nov 7; 161: 547–9Google Scholar
- 11.Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part II. The cost-effectiveness of SSRIs in treatment of depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997Google Scholar
- 16.Mitchell J, Greenberg J, Finch K, et al. Effectiveness and economic impact of antidepressant medications: a review. Am J Man Care 1997; 3: 323–30Google Scholar
- 19.Hylan TR, Neslusan CA, Baldridge RM, et al. SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. J Clin Outcome Measures 1997; 4: 16–22Google Scholar
- 20.Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Man Care 1996; 2: 1239–46Google Scholar
- 22.Depression Guideline Panel. Depression in primary care. Vol. 2 Treatment of major depression. Rockville (MD): US Department of Health and Human Studies, 1993 (Agency for Health Care Policy and Research Publication 93-0551)Google Scholar
- 24.Ereshefsky L. Antidepressants: a pharmacologic rationale for treatment and product selection. Formulary 1995; 30 (1 Suppl.): S10–9Google Scholar
- 25.Streja DA, Hui RL, Streja E, et al. Selective contacting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants. Am J Man Care 1999 Sept; 5 (9): 1133–42Google Scholar
- 26.Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: results from the managed care outcomes project. Am J Man Care 1996 Mar; 11 (3): 253–64Google Scholar
- 27.Horn SD, Sharkey PD, Gassaway J. Managed Care Outcomes Project: study design, baseline patient characteristics, and outcome measures. Am J Manage Care 1996; 2: 237–47.Google Scholar
- 28.Ross-Degnan D, Soumerai SB. HMO formularies and care costs [letter]. Lancet 1996 May 4; 347: 1264Google Scholar
- 31.Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br J Psychiatry 1995; 310: 1433–8Google Scholar